A Phase III, Observer-blind, Randomized, Multicenter Study to Evaluate Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix Porcine Circovirus (PCV)-Free Liquid as Compared to GSK's Rotarix Liquid, Given in 2-doses in Healthy Chinese Infants Starting at Age 6-16 Weeks

The purpose of this study is to evaluate the immunogenicity, reactogenicity and safety of the Porcine circovirus (PCV)-free liquid formulation of GlaxoSmithKline Biologicals' SA (GSK) oral live attenuated human rotavirus (HRV) study intervention compared to GSK's liquid oral live attenuated HRV study intervention in healthy Chinese infants 6 to 16 weeks of age at the time of the first study intervention administration.

Start Date01 Sep 2023

Sponsor / Collaborator

GSK Plc

NCT05496231 / Active, not recruitingPhase 2

A Phase 1/2 Randomized, Observer-blinded, Multi-country Study to Evaluate Safety and Immunogenicity of Investigational Adjuvanted Human Papillomavirus Vaccine in Females (16 to 26 Years of Age)

The Main purpose of this study is to evaluate the safety and reactogenicity of GlaxoSmithKline Biologicals SA (GSK)'s investigational adjuvanted human papillomavirus (HPV) vaccine formulations.

Start Date22 Aug 2022

Sponsor / Collaborator

GSK Plc

NCT04658914 / Active, not recruitingPhase 2IIT

Human Challenge With Live-attenuated Rotavirus to Assess Next-generation Rotavirus Vaccines in Africa

Despite the widespread introduction of vaccines against Rotavirus, Rotavirus continues to be a cause of significant morbidity and mortality in the developing world. This study will assess protection against rotavirus infection and investigate immune correlates of protection following vaccination with a novel trivalent VP8 subunit rotavirus vaccine used alone or in combination with oral rotavirus vaccine.

Start Date15 Apr 2021

Sponsor / Collaborator

Centre For Infectious Disease Research

[+5]

100 Clinical Results associated with Human rotavirus, live attenuated(GlaxoSmithKline Plc)

100 Translational Medicine associated with Human rotavirus, live attenuated(GlaxoSmithKline Plc)

100 Patents (Medical) associated with Human rotavirus, live attenuated(GlaxoSmithKline Plc)

549

Literatures (Medical) associated with Human rotavirus, live attenuated(GlaxoSmithKline Plc)

01 Aug 2024·VIRUS RESEARCH

Circulating rotavirus strains in children with acute gastroenteritis in Iran, 1986 to 2023 and their genetic/antigenic divergence compared to approved vaccines strains (Rotarix, RotaTeq, ROTAVAC, ROTASIIL) before mass vaccination: Clues for vaccination policy makers

Review

Author: Jalilvand, Somayeh ; Latifi, Tayebeh ; Roohvand, Farzin ; Kachooei, Atefeh ; Behnezhad, Farzane ; Mirhoseinian, Mahtab ; Hoseini-Fakhr, Somayeh-Sadat ; Shoja, Zabihollah

In the present study, first, rotaviruses that caused acute gastroenteritis in children under five years of age during the time before the vaccine was introduced in Iran (1986 to 2023) are reviewed. Subsequently, the antigenic epitopes of the VP7 and VP4/VP8 proteins in circulating rotavirus strains in Iran and that of the vaccine strains were compared and their genetic differences in histo-blood group antigens (HBGAs) and the potential impact on rotavirus infection susceptibility and vaccine efficacy were discussed. Overall data indicate that rotavirus was estimated in about 38.1 % of samples tested. The most common genotypes or combinations were G1 and P[8], or G1P[8]. From 2015 to 2023, there was a decline in the prevalence of G1P[8], with intermittent peaks of genotypes G3P[8] and G9P[8]. The analyses suggested that the monovalent Rotarix vaccine or monovalent vaccines containing the G1P[8] component might be proper in areas with a similar rotavirus genotype pattern and genetic background as the Iranian population where the G1P[8] strain is the most predominant and has the ability to bind to HBGA secretors. While the same concept can be applied to RotaTeq and RotasIIL vaccines, their complex vaccine technology, which involves reassortment, makes them less of a priority. The ROTASIIL vaccine, despite not having the VP4 arm (P[5]) as a suitable protection option, has previously shown the ability to neutralize not only G9-lineage I strains but also other G9-lineages at high titers. Thus, vaccination with the ROTASIIL vaccine may be more effective in Iran compared to RotaTeq. However, considering the rotavirus genotypic pattern, ROTAVAC might not be a good choice for Iran. Overall, the findings of this study provide valuable insights into the prevalence of rotavirus strains and the potential effectiveness of different vaccines in the Iranian and similar populations.

25 Jul 2024·The Journal of infectious diseases

Differences in Rotavirus Shedding and Duration by Infant Oral Rotavirus Vaccination Status in Dhaka, Bangladesh, 2011–2014

Article

Author: Lopman, Benjamin ; Colgate, E Ross ; Lee, Benjamin ; Zaman, K ; Petri, William A ; Rogawski McQuade, Elizabeth T ; Ciszewski, Jenna ; Haque, Rashidul ; Taniuchi, Mami ; Platts-Mills, James A ; Kirkpatrick, Beth D

Abstract:

To evaluate how breakthrough rotavirus disease contributes to transmission, we examined the impact of rotavirus vaccination on fecal shedding and duration of illness. We used multivariable linear regression to analyze rotavirus quantity by RT-qPCR and duration among 184 episodes of rotavirus diarrhea positive by ELISA in the PROVIDE study. Vaccinated children had less fecal viral shedding compared to unvaccinated children (mean difference = −0.59 log copies per gram of stool; 95% confidence interval [CI], −.99 to −.19). Duration of illness was on average 0.47 days (95% CI, −.23 to 1.17 days) shorter among vaccinated children. Rotarix vaccination reduces shedding burden among breakthrough cases of rotavirus gastroenteritis.Clinical Trials Registration . NCT01375647.

01 Jul 2024·Heliyon

Comparative analysis of the RVA VP7 and VP4 antigenic epitopes circulating in Iran and the Rotarix and RotaTeq vaccines

Article

Author: Fallah, Tina ; Mansour Ghanaiee, Roxana ; Karimi, Abdollah ; Mahmoudi, Sussan ; Zahraei, Seyed Mohsen ; Alebouyeh, Masoud

Analyzing the lineages and detecting antigenic variation in immunogenic motifs of Group A Rotavirus (RVA) variants is crucial because it can impact vaccine efficacy. This study investigated the circulating lineages of VP4 and VP7 proteins of human RVA isolates and their phylogeny in ≤24-month-old symptomatic, rotavirus-positive children with transudative diarrhea within 48 h of admission to Mofid Children's Hospital between December 2020 and March 2022 in Tehran, Iran. Antigen detection was performed by ELISA, RNA extraction, and semi-nested multiplex PCR for G/P genotypes, followed by sequencing and bioinformatic analysis using multiple sequence alignments in MEGA and phylogenetic analysis by Geneious Prime. The similarity of VP7 and VP4 amino acids with the RotaTeq and Rotarix vaccine strains for cytotoxic T cell and antigenic epitopes was evaluated using the UCSF Chimera Molecular Modeling System. Overall, 27.3 % of the samples were RVA positive, showing untypeable (2.5 %), single (76.9 %), and mixed (20.5 %) genotypic characteristics. The strains clustered in the G1/II, G2/IV, G3/I, G4/I, G9/III, P (Kachooei et al., 2023) [8]/III, P (Howley et al., 2020) [4]/V, and P (Wahyuni et al., 2021) [6]/I lineages. Comparative analysis of VP7 antigenic epitopes showed that the G1/II strains were completely conserved, while the G2/IV, G3/I, G4/I, G6, G9/III strains contained 2, 3-5, 2, 4 and 9 amino acid substitutions, respectively. The P (Kachooei et al., 2023) [8]/III genotypes differed by 3 amino acids, while the P (Wahyuni et al., 2021) [6]/I genotype had the most substitutions. CTL epitopes were completely conserved in G3/I strains, but other genotypes differed by 1-4 amino acids compared to the vaccine strains. Given the diversity of circulating RVA genotypes and the observed mutations in neutralizing and CTL epitopes, immune escape by some of the strains is likely in Iran. This finding underscores the importance of evaluating the effect of rotavirus vaccines on local genotypes and related lineages before implementing a vaccination program.

News (Medical) associated with Human rotavirus, live attenuated(GlaxoSmithKline Plc)

24 Sep 2024

·www.businesswire.com

Foundation Medicine Awarded Contract by the U.S. Department of Veterans Affairs to Provide Tumor Molecular Profiling to Veterans with Cancer

BOSTON--( BUSINESS WIRE )-- Foundation Medicine, Inc. today announced it was awarded its second consecutive, five-year contract by the U.S. Department of Veterans Affairs (VA) to provide tumor molecular profiling tests and services to eligible Veterans living with cancer as part of the VA’s National Precision Oncology Program. The national contract covers Foundation Medicine’s tissue-based test FoundationOne ® CDx, liquid-based test FoundationOne ® Liquid CDx, tissue-based RNA sequencing test FoundationOne ® RNA and FoundationOne ® Heme for hematologic malignancies. Foundation Medicine’s high-quality diagnostic tests being provided to the VA accurately identify the genomic mutations driving a patient’s cancer and match a patient to the most effective treatment options, including targeted therapies, immunotherapies or clinical trials. “We are honored to continue our relationship with the VA’s National Precision Oncology Program to provide Veterans with high-quality diagnostic testing,” said Annie Murphy, chief commercial officer at Foundation Medicine. “We know that delivering the right answers requires the confidence that tests reliably produce accurate results. Our comprehensive portfolio of tissue and blood-based tests can simplify complex decisions by generating quality information to enable better decision-making, patient outcomes and treatment options.” Foundation Medicine was awarded its first contract by the VA in 2019 to provide FoundationOne CDx and FoundationOne ® Liquid for solid tumors as well as FoundationOne Heme for hematologic malignancies. Foundation Medicine and FoundationOne ® are registered trademarks of Foundation Medicine, Inc. About Foundation Medicine: Your Essential Partner in Cancer Care Foundation Medicine is a pioneer in molecular profiling for cancer, working to shape the future of clinical care and research. We collaborate with a broad range of partners across the cancer community and strive to set the standard for quality, scientific excellence, and regulatory leadership. Our deep understanding of cancer biology helps physicians make informed treatment decisions for their patients and empowers researchers to develop new medicines. Every day, we are driven to help our partners find answers and take action, enabling more people around the world to benefit from precision cancer care. For more information, please visit us on www.FoundationMedicine.com and follow us on LinkedIn and X . About FoundationOne ® CDx FoundationOne ® CDx is a next-generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens. FoundationOne CDx is for prescription use only and is intended as a companion diagnostic to identify patients who may benefit from treatment with certain targeted therapies in accordance with their approved therapeutic product labeling. Additionally, FoundationOne CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy. For a full list of targeted therapies for which FoundationOne CDx is indicated as a companion diagnostic, please visit www.F1CDxLabel.com . About FoundationOne ® Liquid CDx FoundationOne ® Liquid CDx is a qualitative next generation sequencing based in vitro diagnostic test for prescription use only that uses targeted high throughput hybridization-based capture technology to analyze 324 genes utilizing circulating cell-free DNA (cfDNA) isolated from plasma derived from anti-coagulated peripheral whole blood of advanced cancer patients. The test is FDA-approved to report short variants in over 300 genes and is a companion diagnostic to identify patients who may benefit from treatment with specific therapies (listed in Table 1 of the Intended Use) in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Patients who are negative for companion diagnostic mutations should be reflexed to tumor tissue testing and genomic alteration status confirmed using an FDA-approved tumor tissue test, if feasible. For the complete label, including companion diagnostic indications and complete risk information, please visit www.F1LCDxLabel.com . About FoundationOne ® RNA FoundationOne ® RNA is a laboratory developed test that was developed and its performance characteristics determined by Foundation Medicine. FoundationOne RNA has not been cleared or approved by the U.S. Food and Drug Administration. FoundationOne RNA is a test for solid tumors which utilizes RNA sequencing to interrogate 318 cancer-related genes to capture gene fusions and rearrangements. A negative result does not rule out the presence of an alteration. Genomic findings are not prescriptive or conclusive for labeled use of any specific therapeutic product. About FoundationOne ® Heme FoundationOne ® Heme is a laboratory developed test that was developed and its performance characteristics determined by Foundation Medicine. FoundationOne Heme has not been cleared or approved by the U.S. Food and Drug Administration. For more information on FoundationOne Heme, please see its Technical Specifications at foundationmedicine.com/heme . The test employs RNA sequencing in addition to DNA sequencing to simultaneously detect all classes of genomic alterations, including base pair substitutions, insertions and deletions, copy number alterations and rearrangements, and gene fusions.

03 Sep 2024

·www.businesswire.com

U.S. Food and Drug Administration Approves FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for Lynparza® (olaparib) in Combination with Abiraterone for Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

BOSTON--( BUSINESS WIRE )-- Foundation Medicine, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne ® CDx and FoundationOne ® Liquid CDx to be used as companion diagnostics for AstraZeneca’s and Merck’s (known as MSD outside of the United States and Canada) Lynparza ® (olaparib) in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). This decision from the FDA follows the approval of FoundationOne CDx for Lynparza to identify mCRPC patients with homologous recombination repair (HRR) gene alterations and the approval of FoundationOne Liquid CDx for Lynparza to identify patients with BRCA1 , BRCA2 and/or ATM alterations in mCRPC. Prostate cancer is one of the most common cancers in men. 1 BRCA1- or BRCA2-mutated mCRPC is a particularly aggressive form of the disease, 2 occurring in approximately 11% of diagnoses. 3 Despite progress in developing new treatment options for this condition, BRCA1- or BRCA2-mutated mCRPC remains difficult to treat and patients often face a poor prognosis. 4 “This approval reinforces the importance of testing for genomic mutations at metastatic diagnosis to help guide treatment decisions,” said Mia Levy, M.D., Ph.D., chief medical officer at Foundation Medicine. “Our high-quality tissue and liquid biopsy companion diagnostic tests will allow more patients to access genomic testing, regardless of specimen type, and will simplify complex decisions by generating the best information to enable better decision-making. There is a critical unmet need for first-line treatment options for patients with BRCA-mutated metastatic castration-resistant prostate cancer and this combination therapy is an important advancement.” Foundation Medicine is the only company with an FDA-approved portfolio of tissue and blood-based comprehensive genomic profiling tests. Using a tissue sample, the FDA-approved FoundationOne CDx test analyzes more than 300 cancer-related genes for genomic alterations in a patient’s tumor. From a simple blood sample, FoundationOneLiquid CDx analyzes more than 300 cancer-related genes to provide genomic insights. With today’s approval, Foundation Medicine is the only company that has seven FDA-approved companion diagnostic indications for prostate cancer. 5 Foundation Medicine is the global leader in companion diagnostic approvals. The company has 60% of all U.S. companion diagnostic approvals for next-generation sequencing (NGS) testing. 6 “This is an important milestone for men with aggressive prostate cancer,” said Courtney Bugler, President and CEO of ZERO Prostate Cancer. “Biomarker testing is an important tool for patients and families to help facilitate personalized treatment decision making, and we applaud Foundation Medicine for these additional companion diagnostic indications.” Lynparza is jointly developed and commercialized by AstraZeneca and Merck. Foundation Medicine and FoundationOne ® are registered trademarks of Foundation Medicine, Inc. About Foundation Medicine: Your Essential Partner in Cancer Care Foundation Medicine is a pioneer in molecular profiling for cancer, working to shape the future of clinical care and research. We collaborate with a broad range of partners across the cancer community and strive to set the standard for quality, scientific excellence, and regulatory leadership. Our deep understanding of cancer biology helps physicians make informed treatment decisions for their patients and empowers researchers to develop new medicines. Every day, we are driven to help our partners find answers and take action, enabling more people around the world to benefit from precision cancer care. For more information, please visit us on www.FoundationMedicine.com and follow us on LinkedIn and X . About FoundationOne ® CDx FoundationOne ® CDx is a next-generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens. FoundationOne CDx is for prescription use only and is intended as a companion diagnostic to identify patients who may benefit from treatment with certain targeted therapies in accordance with their approved therapeutic product labeling. Additionally, FoundationOne CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy. For a full list of targeted therapies for which FoundationOne CDx is indicated as a companion diagnostic, please visit www.F1CDxLabel.com . About FoundationOne ® Liquid CDx FoundationOne ® Liquid CDx is a qualitative next generation sequencing based in vitro diagnostic test for prescription use only that uses targeted high throughput hybridization-based capture technology to analyze 324 genes utilizing circulating cell-free DNA (cfDNA) isolated from plasma derived from anti-coagulated peripheral whole blood of advanced cancer patients. The test is FDA-approved to report short variants in over 300 genes and is a companion diagnostic to identify patients who may benefit from treatment with specific therapies (listed in Table 1 of the Intended Use) in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Patients who are negative for companion diagnostic mutations should be reflexed to tumor tissue testing and genomic alteration status confirmed using an FDA-approved tumor tissue test, if feasible. For the complete label, including companion diagnostic indications and complete risk information, please visit www.F1LCDxLabel.com . ____________________________ 1 Cancer.net. Prostate Cancer: Statistics. Updated March 2023. Accessed August 19, 2024. https://www.cancer.net/cancer-types/prostate-cancer/statistics 2 Castro E, Eeles R. The role of BRCA1 and BRCA2 in prostate cancer. Asian J Androl. 2012;14(3):409-414. https://doi.org/10.1038/aja.2011.150 3 Valsecchi AA, Dionisio R, Panepinto O, et al. Frequency of Germline and Somatic BRCA1 and BRCA2 Mutations in Prostate Cancer: An Updated Systematic Review and Meta-Analysis. Cancers. 2023; 15(9):2435. https://doi.org/10.3390/cancers15092435 4 Messina C, Cattrini C, Soldato D, et al. BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications. J Oncol. 2020;2020:4986365. Published 2020 Sep 7. https://doi.org/10.1155/2020/4986365 5 Data on File, Foundation Medicine, Inc. 2024 6 Data on File, Foundation Medicine, Inc., data as of March 2024

Drug Approval

100 Deals associated with Human rotavirus, live attenuated(GlaxoSmithKline Plc)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J07BH01	DB10276

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Rotavirus Infections	JP	GSK Plc	01 Jul 2011
Viral gastroenteritis due to Rotavirus	EU	GlaxoSmithKline Biologicals SA	21 Feb 2006
Viral gastroenteritis due to Rotavirus	IS	GlaxoSmithKline Biologicals SA	21 Feb 2006
Viral gastroenteritis due to Rotavirus	LI	GlaxoSmithKline Biologicals SA	21 Feb 2006
Viral gastroenteritis due to Rotavirus	NO	GlaxoSmithKline Biologicals SA	21 Feb 2006

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Norovirus Infections	Phase 3	CN	GSK Plc	01 Sep 2023
Pneumococcal Infections	Phase 3	TH	Sanofi Pasteur	28 Jun 2020
Meningitis, Haemophilus	Phase 3	KR	GSK Plc	04 Mar 2011
Gastroenteritis	Phase 3	CN	GlaxoSmithKline (China) Investment Co., Ltd.	29 Aug 2010
Gastroenteritis	Phase 3	CN	GlaxoSmithKline Biologicals SA	29 Aug 2010
Pneumonia, Pneumococcal	Phase 3	MX	GSK Plc	03 Jul 2007
Fever	Phase 3	CZ	GSK Plc	01 Sep 2006
Hepatitis B	Phase 2	-	GSK Plc	01 Jan 2001

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02847026 (Pubmed) Manual	Phase 4	Rotavirus Infections	1,144	RotaTeq	pzkayurqdm(dnfadfhzgs) = xuiuqjbzpy oinxozfoex (ihpayhlhxp ) View more	Positive	09 Aug 2022
				Rotarix	pzkayurqdm(dnfadfhzgs) = lgvbvcyjyu oinxozfoex (ihpayhlhxp ) View more
NCT02941107 (ORVAC, Pubmed \| Am J Trop Med Hyg)	Phase 4	-	253	Rotarix	huvpjwcaog(yxwbxcempk) = ycjtqgiold itedjgflro (qjvdpvwdzy )	Positive	04 Feb 2022
				Placebo	huvpjwcaog(yxwbxcempk) = xqeedumzhk itedjgflro (qjvdpvwdzy )
NCT02141204 (CTgov)	Phase 3	Rotavirus Infections	451	HRV Liquid (HRV Liq Group)	zdpxvuelwi(ekmyrkaxyh) = mipciwggdm jgrpomeqfa (ptgookgvov, qwcjtljvcj - ckaeozrprk) View more	-	09 Dec 2020
				HRV Lyophilized (HRV Lyo Group)	zdpxvuelwi(ekmyrkaxyh) = claosmpgta jgrpomeqfa (ptgookgvov, ucgjmnbevx - mpdaceuwph) View more
NCT02992197 (CTgov)	Phase 4	Rotavirus Infections	220	Placebo (for Rotarix dose 2)+Rotarix, dose 1 (Rotarix, Single Dose)	znfqmbjnzq(qifzjqnidn) = iwcnzlfvtt tbvjsclwjs (aekcxokltd, znvchrfflv - nmsomvmhno) View more	-	17 Jul 2020
				Rotarix, dose 2 (Rotarix, Double Dose)	znfqmbjnzq(qifzjqnidn) = zvrndestbl tbvjsclwjs (aekcxokltd, wfejzadbda - rubfipcbiy) View more
NCT03207750 (CTgov)	Phase 3	Rotavirus Infections \| Viral gastroenteritis due to Rotavirus	1,280	human rotavirus (HRV) vaccine+Hiberix+Prevnar-13+Pediarix (HRV Porcine Circovirus (PCV)-Free Liquid Group)	pfcujblmom(cporxozoly) = zvbvekvnpc cqullbjxso (xkaxbjvfww, qrxnmcosry - utfiteapqy) View more	-	31 Oct 2019
				human rotavirus (HRV) vaccine+Hiberix+Prevnar-13+Pediarix (HRV Lyophilized Group)	pfcujblmom(cporxozoly) = jtpbtwuqwi cqullbjxso (xkaxbjvfww, wacnmhoknc - mqofdansdq) View more
NCT02914184 (CTgov)	Phase 3	Rotavirus Infections \| Viral gastroenteritis due to Rotavirus	1,612	HRV PCV-free liquid vaccine (Liq_A Group)	bfjayxqddc(wcibxdhrws) = uyeibdgctg ptbpwosqbj (qfjjytwdur, mnnimlzgae - jypdscqopt) View more	-	14 Oct 2019
				HRV PCV-free liquid vaccine (Liq_B Group)	bfjayxqddc(wcibxdhrws) = urincyqehq ptbpwosqbj (qfjjytwdur, jgvvwhnoet - enqtgtvdxt) View more
NCT01700621 (CTgov)	Phase 4	Rotavirus Infections \| Rubella \| Measles	482	Rotarix vaccine+measles-rubella vaccine (Measles-rubella and Rotavirus Vaccines)	yrexmsgbqp(nnhoranjmr): Seroconversion proportion difference = 1.1 (95% CI, -6.9 to 9.0)	-	18 Feb 2019
				measles-rubella vaccine (Measles-rubella Vaccine)
NCT02907216 (CTgov)	Phase 4	Diphtheria \| Rotavirus Infections \| Whooping Cough ... View more	292	Squarekids+Rotarix (Co-administration Group)	snvwtuxtzu(zhytbijcro) = erzbuaqxlm mexdwgefqj (rthafuwjtz, lzysgieeut - rjgebpdbgl) View more	-	23 Jan 2019
				Squarekids+Rotarix (Staggered Group)	snvwtuxtzu(zhytbijcro) = ecevhliwzb mexdwgefqj (rthafuwjtz, qvpwkcerxd - crceavvpwe) View more
NCT02542462 (CTgov)	Phase 4	Rotavirus Infections \| Intussusception	144	Rotarix®, (Rotarix® Alone)	thsnrzrheb(ghtklomgsd) = gdxgyxscdc kqqnkihbsb (etqzhgbeqq, pzrghktiav - bogqaxgtlg) View more	-	12 Jul 2018
				routine vaccines+Rotarix® (Rotarix®,With Other Routine Vaccines)	thsnrzrheb(ghtklomgsd) = wfeizopeeq kqqnkihbsb (etqzhgbeqq, qloihkutac - xrgxjmgfif) View more
NCT00432380 (CTgov)	Phase 2	Rotavirus Infections \| Viral gastroenteritis due to Rotavirus	375	Placebo+Rotarix™ (Placebo-Rotarix-Rotarix Group)	pdvxluhccl(zeianzedcy) = tgjnvpefcg jgvpnrytfk (fsudfjrpxk, ntkbgjgiay - samcvyufof) View more	-	11 Sep 2017
				Placebo+Rotarix™ (Rotarix-Placebo-Rotarix Group)	zakmkuqrgf(kocaowrwhp) = oqecdezcnw acjhtjjvlb (drcrxqvtrf, xlgdjkwhwz - jmjligwpba) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Human rotavirus, live attenuated(GlaxoSmithKline Plc)

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation